Cancer is a global challenge, impacting lives and families in countless ways.

Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Perimeter envisions a world where patients no longer experience the emotional and physical trauma of a second operation due to cancer left behind.

The Re-Excision Challenge

Surgeons have worked tirelessly to solve for intraoperative margin assessment, with the ultimate goal of improving survivability and quality of life. Yet, getting clean margins during the initial surgery still remains one of their most pressing problems, recognized by professional societies as the “re-excision epidemic.”

If margins are positive, patients typically return for another surgery, impacting them physically, emotionally and financially, delaying adjunct treatments and getting back to their lives.

Even for skilled surgeons using the latest techniques, the odds of needing a repeat surgery are relatively high—nearly 1 in 4 for some types of cancer:

21% of breast lumpectomies require re-excision12
11.5% of thyroid cancers have a positive margin9
21% of prostate cancers have a positive margin9

It’s All About Getting Clean Margins

Surgeons will do everything they can to achieve clean margins but they cannot detect remaining cancer cells—especially with hard-to-detect cancers—by sight or touch.

Traditional imaging used in the operating room, such as X-ray, does not have the resolution needed to detect microscopic cancer cells, and Pathology must be used to confirm clean margins, which takes up to a week.

The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. More information here.

A Game Changer for Margin Management

Perimeter’s proprietary Optical Coherence Tomography (OCT) technology provides high-definition, 3D images of margins in the operating room. This has the potential to give surgeons clarity on margin status so they can make decisions to take more tissue at the point of care, not days later when pathology reports come back.

Optical Coherence Tomography (OCT), developed out of MIT in 1991, gives surgeons the resolution to help visualize hard-to-detect tissue microstructures associated with early-stage cancers.2

Simply put, we provide advanced margin imaging in the moment – when it matters most.

Continue Exploring



News & Events

Ready to learn more about Perimeter?

Get Started